Company news: Forest Labs

Share this article:
FDA approved Forest's Daliresp (roflumilast) for the treatment of severe chronic COPD in adults 18 and up. The daily pill is indicated for decreasing the frequency of flare-ups or worsening of symptoms including breathlessness, chronic cough and excessive phlegm associated with bronchitis. The first-in-class drug is not indicated for treatment of primary emphysema, another form of COPD.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions